HER2-positive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The poor prognostic effect of diabetes in HER-2+ breast cancer patients could be associated with the high levels of HER-3 and neuregulin 1, thus it should be considered and evaluated more.
|
30927244 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study examined the anticancer efficacy of dual HER2 and HER3 blockade in trastuzumab-resistant HER2-positive breast cancer.
|
30701699 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
|
30317526 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we demonstrate that HER3 inhibition by miR-205 ectopic expression or siRNA-mediated silencing improves the responsiveness to Trastuzumab <i>in vitro</i> in HER2+ BC cell lines, and that this effect is exerted through impairment of AKT-mediated pathway.
|
29963251 |
2018 |
HER2-positive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We sought to investigate the role of patient-derived HER3 mutations in ER+ and HER2+ breast cancer cells using ectopic expression of HER3 mutants.
|
29963236 |
2018 |
HER2-positive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HER3 expression may be a useful factor for predicting the response of HER2-positive breast cancer to chemotherapy with the TPD regimen.
|
29599351 |
2018 |
HER2-positive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of our study suggest that combined analysis of HER3 and PTEN expression might bring information on trastuzumab sensitivity in the group of HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
|
28123607 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Some miRNAs are associated with resistance to HER2-targeted therapy and HER3 expression in HER2-positive breast cancer.
|
27439682 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using next generation sequencing (NGS) we identified ERBB-family (EGFR, HER2, HER3 and HER4) single nucleotide polymorphisms (SNPs) that occurred in 2 or more patients of a 32 HER2-positive BC patient cohort.
|
27776352 |
2016 |
HER2-positive carcinoma of breast
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Exogenous palmitate reduces HER2 and HER3 protein levels without changes in phosphorylation and sensitizes HER2/neu-positive breast cancer cells to treatment with the HER2-targeted therapy trastuzumab.
|
27464732 |
2016 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
As current strategies to treat HER2-positive breast cancer are unable to inhibit this feedback response, two great promises emerged: the combination of targeted-therapies and drugs targeting HER3.
|
25712189 |
2015 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
|
24044505 |
2013 |
HER2-positive carcinoma of breast
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We also investigated the effects of acute and chronic Herceptin treatment on HER3 and PKB phosphorylation in HER2-positive breast cancer cells.
|
21203579 |
2010 |